StemRIM (TSE:4599) Change In Receivables : 円0.00 Mil (TTM As of Jul. 2024)

View and export this data going back to 2019. Start your Free Trial

What is StemRIM Change In Receivables?

StemRIM's change in receivables for the quarter that ended in Jul. 2024 was 円0.00 Mil. It means StemRIM's Accounts Receivable stayed the same from Apr. 2024 to Jul. 2024 .

StemRIM's change in receivables for the fiscal year that ended in Jul. 2024 was 円-187.14 Mil. It means StemRIM's Accounts Receivable increased by 円187.14 Mil from Jul. 2023 to Jul. 2024 .

StemRIM's Accounts Receivable for the quarter that ended in Jul. 2024 was 円0.00 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. StemRIM's liquidation value for the three months ended in Jul. 2024 was 円8,239.24 Mil.

StemRIM Change In Receivables Historical Data

The historical data trend for StemRIM's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

StemRIM Change In Receivables Chart

StemRIM Annual Data

Trend

Jul17

Jul18

Jul19

Jul20

Jul21

Jul22

Jul23

Jul24

Change In Receivables

Get a 7-Day Free Trial

41.85

-37.26

-66.23

103.49

-187.14

StemRIM Quarterly Data
	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

StemRIM Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jul. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.00 Mil.

StemRIM (TSE:4599) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

StemRIM's Days Sales Outstanding for the quarter that ended in Jul. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, StemRIM's accounts receivable are only considered to be worth 75% of book value:

StemRIM's liquidation value for the quarter that ended in Jul. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8410.449	-	185.881	+	0.75 * 0	+	0.5 * 29.334
=	8,239.24

StemRIM Change In Receivables Related Terms

Thank you for viewing the detailed overview of StemRIM's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

StemRIM Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » StemRIM Inc (TSE:4599) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

7-15 Ayato Bio Incubator 3rd floor, Ayato Asagi 7-chome, Prefecture Ibaraki City, Osaka, JPN, 567-0085

Website

https://www.stemrim.com

StemRIM Inc is a biotechnology company engaged in developing regeneration-guided medicines. The business activity of the group includes research, development, manufacture, and sales of pharmaceuticals and medical devices and products such as gene therapy that activate stem cells existing in the body and induce regeneration of damaged tissue.

StemRIM Headlines

No Headlines